Effects of gemfibrozil on serum lipids.
A two-part, multicenter study to assess the clinical efficacy, side effects, and safety of gemfibrozil in 427 patients over treatment durations of up to 13 months showed that this drug markedly reduces the level of serum triglycerides, while moderately lowering total serum cholesterol levels. The high-density lipoprotein cholesterol level was substantially increased, with concomitant decreases in low-density lipoprotein and very low-density lipoprotein cholesterol levels. The drug was generally well tolerated. However, a potential for increasing blood glucose levels was noted and careful monitoring during therapy is recommended.
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D008055:Lipids; D010421:Pentanoic Acids; D014631:Valerates; D015248:Gemfibrozil